This finding may explain some surprising results from mutational analyses of PTEN in different cancers, which revealed frequent hyperactivation of AKT signalling in the absence of identifiable PTEN mutations (reviewed in Cully et al. 2006). The gene discussed is AKT1; the disease is cancer.